XXXX treatment in @entity9335 : a double-blind controlled trial with monitoring of exposure to ultraviolet radiation.

@entity1 @entity500 @entity1910 @entity2264 @entity9335 @entity24825
Oral @entity500 was compared with placebo in a double-blind controlled trial of therapy in @entity9335 ( @entity9335 ), a rare @entity24825 . Eighteen severely affected @entity1 were randomly allocated to @entity500 50 mg t.d.s. or placebo over a 2-year period. Severity of itch and @entity1910 were assessed weekly by each @entity1 on a visual analogue scale and overall clinical status monthly by a medical observer. Monitoring of @entity1 ultraviolet radiation (UVR) exposure was undertaken throughout treatment by @entity2264 film lapel-badge dosimetry. Five of 8 @entity1 treated with @entity500 but none of 10 placebo @entity1 achieved remission within 6 months. One @entity1 could not tolerate treatment because of gastrointestinal effects. No haematological or hepatic abnormality was noted. The marked improvement in clinical status of actively treated @entity1 (P less than 0.02, Fisher's exact test), led to early termination of the trial. Oral @entity500 therapy is an effective and usually well tolerated treatment in @entity9335 .
